Introduction
Heart disease is the leading cause of death for Americans with $720,000 people experiencing a heart attack every year. 1 Despite advances in reperfusion therapy, incomplete myocardial revascularization remains as high as 37% after coronary artery bypass grafting and 43% after percutaneous coronary intervention. 2 After an ischaemic event, myocyte necrosis and subsequent alteration of the loading pattern activate a cascade of neurohormonal signalling that mediates cardiac remodelling through ventricular dilatation, hypertrophy, and the formation of a collagen scar. Though this remodelling may temporarily preserve cardiac output, progressive remodelling is maladaptive and leads to further ventricular dilatation and potentially heart failure. 3 Therapeutic angiogenesis is a potential strategy to foster new vessel formation in the ischaemic peri-infarct border zone and to subsequently improve post-infarction ventricular remodelling and cardiac function. However, studies investigating the direct injection of progenitor cells into the myocardium to improve local angiogenesis have struggled with low cell retention and viability. 4, 5 Nevertheless, recent studies have demonstrated the persistence of the therapeutic effect of myocardially transplanted cells in the absence of cell engraftment, suggesting the potential for paracrine mechanisms derived from the cell secretome as the therapeutic mediators. 6, 7 Extracellular vesicles (EVs), including exosomes and microvesicles, have garnered significant interest due to their key roles in paracrine signalling with angiogenic, proliferative, and antiapoptotic effects. 8, 9 Exosomes are nanovesicles with characteristic size of 40-120 nm formed by the budding of the endosomal membrane into a multivesicular body created by the inward invagination of the lipid bilayer plasma membrane. In contrast, microvesicles range from 50 to 1000 nm and are formed by the outward budding of the plasma membrane resulting in vesicular membranes that closely resemble that of the cell. 10 Though exosomes are more uniform in size and protein content, significant overlap in function exists between exosomes and microvesicles. A wide range of signalling molecules including proteins, mRNA, and miRNA, are transported within exosomes and microvesicles to mediate cross-talk between cells. 11, 12 The potential for replicating the angiogenic activity of progenitor cells using EVs alone while eliminating the complexities associated with cell transplantation and survival is a very attractive strategy.
We hypothesize that this cell-free therapy will confer several distinct advantages over current cell therapies. Unlike cells, EVs can be produced and isolated in large quantities, frozen indefinitely, thawed, and rapidly prepared for therapeutic use. 13 We postulate that EVs exert their effect on endothelial and myocardial cells over time. Given previous cell-based studies and the small size of EVs, an unacceptably high rate of washout from the myocardium is likely with direct injection. We therefore propose the use of a shearthinning, injectable hyaluronic acid (HA) hydrogel to localize the EVs to the ischaemic border zone through encapsulation within the hydrogel. Our shear-thinning hydrogel (STG) is assembled by guest-host interactions of adamantane-modified HA (Ad-HA) and b-cyclodextrin-modified HA (CD-HA). With the application of shear stress during injection through a syringe, the construct enters a liquid-like state to allow for intramyocardial delivery. It rapidly self-heals at the target site into gel form with removal of shear stress. Through diffusion, swelling, and gel erosion, particle release is achieved over prolonged therapeutic timeframes. These properties permit slow elution of EVs and achieve high local concentrations in the ischaemic border zone.
Our group previously demonstrated that the addition of a STG to endothelial progenitor cell (EPC) treatment further augmented the improvement in cardiac function after myocardial infarction (MI) seen with injection of EPCs alone. 14 The goal of this project is to deliver EPCderived EVs into ischaemic myocardium within a STG to reproduce the benefits of the EPC treatment in a cell-free manner. We hypothesized that delivery of EVs will increase angiogenic activity and provide periinfarct stabilization, thereby decreasing adverse ventricular remodelling and subsequent loss of cardiac function. 
Cell culture
Pooled human umbilical vein endothelial cells (HUVECs) were purchased from Lonza. HUVECs were cultured in EGM-2 and passaged at 70-80% confluence up until Passage 7.
Primary bone marrow-derived rat EPCs were isolated as previously described. 14, 15 Briefly, adult donor rats (350-375 g) were administered pentobarbital via intraperitoneal injection at 100 mg/kg for anaesthesia. After cessation of pedal reflex, euthanasia was performed by transection of the carotid artery, and pneumothorax was induced for confirmation of euthanasia. Following exsanguination, the long bones were collected, and the bone marrow was harvested. Bone marrow mononuclear cells were isolated by density-gradient centrifugation on Histopaque-1083 (Sigma-Aldrich, 10831) and plated on vitronectin-coated 10-cm culture dishes. EPCs were cultured as the adherent fraction in EGM-2 (Lonza, Basel, Switzerland) without heparin or hydrocortisone. After 4 days, media was changed to remove non-adherent cells. All EPCs were used 6-7 days post-isolation. All cells were cultured at 37 C in a humidified incubator with 21% O 2 and 5% CO 2 .
Isolation of EVs
Four days post-isolation, EPCs were changed to serum-free EGM-2 without heparin or hydrocortisone for 48 h. This conditioned media (CM) was cleared of cellular debris and large subcellular contaminants by centrifugation at 2000g for 30 min. EVs were isolated from clarified CM using Total Exosome Isolation reagent (Invitrogen, Carlsbad, CA) following manufacturer's protocol. Briefly, CM was incubated in a 1:2 ratio with the reagent overnight at 4 C, then pelleted by centrifugation at 10 000g in 4 C for 1 h and re-suspended in 0.22 mm-filtered dPBS.
EPC survival after 48 h of culture in serum-free media was quantified (see Supplementary Material online).
Transmission electron microscopy
EV samples fixed in 2% PFA overnight were adhered to a freshly glowdischarged carbon-formvar coated 400-mesh copper grid for 20 min. Grids were negative-stained with two drops of 2% uranyl acetate for 5 min and allowed to air dry. EV preparations were analyzed by transmission electron microscopy (TEM) using a JEOL 1010 (JEOL, Ltd., Tokyo, Japan). Images were acquired using a Hamamatsu digital camera using the AMT Advantage Image Capture Software. Particle size was analyzed using ImageJ software (NIH, Bethesda, MD). 
Nanoparticle tracking analysis
EVs suspended in phosphate buffered saline (PBS) were analyzed using the NanoSight NS500 with green laser at 532 nm (Malvern Instruments, Malvern, UK). Samples were injected manually, and data acquisition was performed at ambient temperature. Data were analyzed with Nanoparticle Tracking Analysis software (NTA 2.2; Malvern).
Mass spectrometry
Protein content of EPCs from cell lysate and EPC-derived EVs was prepared and analyzed by mass spectrometry using MaxQuant version 1. 5 
Tubule formation assay
The angiogenic effect of EVs on HUVECs was quantified using a Matrigel tubule formation assay. Matrigel solution (Corning, Cat no. 354234) was thawed overnight, and 225 ml was plated per well onto a 24-well plate. After a 30-min gelation period at 37 C, 7 Â 10 4 HUVECs were seeded onto each well. HUVECs were incubated with endothelial cell basal media (EBM-2, Lonza) alone, 1 ng/ml vascular endothelial growth factor (VEGF, Sigma), or 4.6 Â 10 9 EVs. After 11 h, the proliferative response of HUVECs to EVs was quantified (see Supplementary Material online). Bright-field micrographs at 4Â were obtained using the EVOS XL Imaging System (Invitrogen). The mean tubule lengths, defined as the length between two nodes, were analyzed using the measuring tool on ImageJ. The number of isolated segments was analyzed the Angiogenesis Analyzer plug-in (Gilles Carpentier).
STG preparation and EV release profile
The formation of the STG was performed as described previously in 14 (see Supplementary Material online). Briefly, hydrogels at 4% w/w were prepared from lyophilized polymers of Ad-HA and CD-HA dissolved in PBS and mixed. The mechanical properties and viscoelastic behaviour of the STG were characterized with an AR2000 stress-controlled rheometer (TA Instruments, New Castle, DE). Encapsulation of EPCs or EVs was performed by dissolving the polymers in PBS suspensions of EPCs or EVs. To assess the time course of EV release, 500 ml of PBS was added on top of gels and incubated at 37 C. On Days 4, 7, 14, and 21, releasates were collected without disturbing the gel and replaced with fresh PBS.
Releasates were stored at -20 C and analyzed with NTA to determine particle release.
Phase II. EV treatment

Rat model of MI
MI was induced by occlusion of the LAD, which is an established model of MI. 15 Animals were randomized into 1 of 5 treatment groups: PBS control (n = 10), STG control (n = 10), EVs in PBS (PBS þ EV, n = 9), EPCs in STG (STG þ EPC, n = 10), and EVs in STG (STG þ EV, n = 11). EPCs or EVs prepared in STG were formed as described and manually transferred to a 1 mL syringe. Animals were induced with 5% isoflurane in an induction chamber, then intubated and mechanically ventilated, with 1-3% isoflurane to maintain a surgical anaesthetic depth for the duration of the procedure. Prior to incision, 0.05 mg/kg of buprenorphine was injected subcutaneously. The chest was entered through a left fourth interspace thoracotomy. The LAD was identified and ligated 1 mm below the level of the left atrial appendage with a resultant anterolateral MI encompassing 30% of the left ventricle (LV). Immediately after infarction, 100 ml of PBS or STG containing 700 000 EPCs or 9.33 Â 10 9 EVs was delivered via 5 Â 20 ml injections around the border zone of the infarcted area. During closure, 1 mg/kg of bupivacaine was injected at the intercostal incision, and meloxicam at 2 mg/kg was injected subcutaneously. Following closure, pneumothorax was evacuated. Animals were recovered on a heating pad and ventilated on room air until spontaneously breathing. For the in vivo studies, the EPCs and EVs were allogenic and pooled from multiple donors. The EVs injected in the STG þ EV experiment group were derived from the EPCs that were injected in the STG þ EPC group.
Measurement of haemodynamics
Four weeks following LAD ligation and treatment injection, haemodynamics were assessed. After induction of anaesthesia with 5% isoflurane, the rat was intubated and mechanically ventilated. Following confirmation of adequate surgical anaesthesia maintained with continuous inhaled 2% isoflurane, a 2Fr pressure-volume catheter (Millar, Inc., Houston, TX) was inserted into the LV in a retrograde fashion via the right common carotid artery. The primary measure of treatment effect in this study was preload-independent contractility as measured by ESPVR, which was determined by temporary occlusion of the inferior vena cava using the methods described by Pacher et al. 16 Additional haemodynamic parameters measured were ejection fraction, cardiac output, the rate of pressure rise in systole (þdP/dt), the rate of ventricular relaxation in diastole (-dP/dt), maximum pressure, end diastolic, end systolic, and stroke volumes, end diastolic pressure-volume relationship (EDPVR), and heart rate.
Immunohistochemical analysis
To assess angiogenesis in the infarct border zone, 10 mm sections taken at the mid-papillary level were stained with conjugated antibodies against Von Willebrand factor (vWF-FITC, ab8822, 1:300) and smooth muscle actin (SMA-AF594, ab202368, 1:300), and WGA-AF647 conjugate (1:300). Images were taken on the Leica DM5000b (Leica, Wetzlar, Germany) at 20Â magnification using a DFC350 FX monochrome camera (Leica). Three high-power fields (HPFs) per animal were taken of the peri-infarct myocardium, defined as one field away from WGA-labelled scar. Each image was manually quantified for total vasculature using ImageJ: areas expressing vWF alone were counted as capillaries, while areas co-expressing vWF and SMA were counted as arterioles. In addition, inflammatory cell infiltration into the peri-infarct border zone was assessed 2 days and 4 weeks after MI and treatment by staining for CD11b (see Supplementary Material online).
Histological analysis
At time of terminal surgery, the hearts were explanted and embedded in OCT (Tissue Tek, Torrance, CA) and frozen on dry-ice. 10 mm transverse sections were taken from the apex to the base of the LV. Sections were stained using Masson's Trichrome (Sigma-Aldrich). Scar thickness, a measure of border zone treatment response, was determined by averaging the distance between the endocardial and epicardium at the scar midpoint and at both ends of the scar on sections taken at the mid-papillary level. All measurements were made using ImageJ. Representative images were taken at the apical, middle, and basal portions of the infarct and imaged using a Nikon P150 camera with Nikkor 42Â wide optical zoom lens.
Statistical analysis
Treatment across groups was randomly generated with animals coded by random identifiers. 
Results
Phase I. EV characterization
Characterization of EPC-derived EVs
Enrichment of EVs from EPC culture media was confirmed by characterization of particle morphology and size distribution. TEM demonstrates the presence of small, round particles and cup-shaped particles between 60 and 120 nm characteristic of microvesicles and exosomes, respectively ( Figure 1A) . NTA on the EV isolate reveals that 80% of the sample falls within the range of 76.8-141.8 nm, with a modal particle diameter of 91.2 ± 2.9 nm ( Figure 1B ). EVs were isolated from serum-free EPC culture media to reduce serum protein and EV contamination. Serum-free conditions reduced EPC survival by 21 .3% (P < 0.01) (see Supplementary material online, Figure SIA) .
To compare EPCs and their released EVs, their proteomic profiles were investigated by mass spectrometry. Our analysis revealed more than 2000 unique proteins within EPCs and their EVs. Of these, 1327 were unique to EPCs, 47 were unique to EVs, and 662 were shared by both. Of note, the top 20 proteins most often found in exosomes, including the tetraspanins CD9, CD63, and CD81, were identified in our EV samples. 17 Figure 1D) . ), are inferred to be present with high probability ( Figure 1C) . Both c-Myc and Sp1 are known to play regulatory roles in the angiogenic pathway. 37 
through endocytosis
Uptake of EVs is essential to mediate their phenotypic effect. To confirm uptake of EPC-derived EVs, we visualized the uptake of CM-DiI-labelled EVs by HUVECs. After a 24-h incubation, confocal imaging showed clear, perinuclear staining of HUVECs with CM-DiI (Figure 2A) . Most experimental evidence points to endocytosis as the primary mechanism of EV uptake. 40, 41 To determine if endocytosis was responsible for EPCderived EV uptake, CytoD, a known destabilizer of actin filaments was used to block uptake. As expected, we observed a dose-dependent decline in CM-DiI signal in HUVECs with CytoD preincubation ( Figure  2B-D) . On further quantification, there was an increase in CM-DiI signal intensity in the supernatant and complementary decrease in signal in the cells. (Figure 2E and F) . These data suggest that endocytosis mediates the uptake of EPC-derived EVs into endothelial cells.
EV Treatment leads to increased organized vessel formation in vitro
Characterization of protein cargo present in EPC-derived EVs provides promising evidence of their potential to independently improve angiogenic activity in the same fashion as other progenitor cell therapies. To assess this, we performed a Matrigel tubule formation assay ( Figure 3) . Mean tubule length was significantly increased after incubation with EVs compared with EBM alone by 14.1% (157.9 ± 3.81 vs. 138.4 ± 2.92 units, Figure 3D ). Incubation with EVs significantly reduced the number of isolated branches by 21% compared with EBM alone (47.5 ± 1.9 vs. 59.7 ± 1.3 branches, P < 0.05, Figure 3e ), indicating an increase in overall organized vessel formation. We did not find a significant difference in HUVEC proliferation after incubation with EBM alone compared with incubation with EVs or VEGF ( Figure 3F ).
Steady release of EVs from STG
In our previous work with STG-encapsulated EPCs, we showed that the gel vehicle potentiated the effect of EPCs by minimizing cell dispersion. 14 We adapted this strategy to in vivo delivery of EVs to increase retention and local delivery of therapy via encapsulation within the STG ( Figure  4A ). The shear-thinning and viscoelastic behaviour of this gel was confirmed by oscillatory rheology ( Figure 4B ). Viscosity decreased with increasing shear rate and stress, displaying classical shear-thinning behavior. With increasing strain, gels yielded and the storage modulus (G') dropped below the loss modulus (G'') to permit flow. Upon cessation of strain, gels rapidly recovered to initial mechanics in which G' predominates over G''. CM-DiI EVs demonstrated even distribution without aggregation throughout the STG when imaged with confocal microscopy ( Figure 4C) . The releasate from the STG þ EV construct was collected over 21 days in vitro and prepared for NTA in five fractions. Analysis showed steady cumulative particle release over 21 days ( Figure 4D ).
Phase II: EV treatment
STG 1 EPC and STG 1 EV treatments improve haemodynamics in a rat model of acute MI
After demonstrating the enhanced angiogenic potential of EPC-derived EVs in vitro and compatibility with the STG, we next sought to establish the impact of EVs in myocardial ischaemia. Four weeks after MI, rat hearts treated with STG þ EV and STG þ EPC showed improvements in haemodynamic function when compared to PBS Control and STG Control. The primary outcome of preload-independent contractility as measured by ESPVR was significantly higher in these groups compared with controls ( Figure 5A) . ESPVR in the STG þ EV cohort was 82% higher compared with PBS Control, 27% higher compared with STG Control, 16% higher compared with the PBS þ EV group, and equivalent compared with STG þ EPC (see Supplementary material online, Figure SII) . When compared with PBS Control, STG þ EV treatment increased left ventricular ejection fraction, cardiac output, maximum rate of systolic pressure change, maximum rate of diastolic pressure change, and maximum pressure ( Figure 5B-F) . These parameters were not statistically different between STG þ EV and STG þ EPC groups. When compared with PBS Control, STG þ EV and STG þ EPC animals had decreased end diastolic and systolic volumes but an overall increase in stroke volume ( Figure 5G-I) . In these groups, decreased left ventricular end diastolic volume provided evidence for the preservation of ventricular geometry. Furthermore, the STG þ EV treatment also improved ventricular compliance, the reciprocal of EDPVR (Figures 5J). No significant trend was observed in heart rate among the treatment groups ( Figure 5K ).
STG 1 EV increases vessel density in peri-infarct myocardium
To better elucidate the mechanisms underlying the haemodynamic improvements observed by the STG þ EV therapy, we assessed vascular density in the peri-infarct myocardium after treatment by looking at expression of vWF, expressed on the luminal side of vascular endothelial cells, and a-SMA, found in the smooth muscle lining arterioles. Overall, vascular density significantly improved in response to STG þ EPC and STG þ EV treatment ( Figure 6 ). Of note, STG þ EV showed significant improvement in microvascular density compared with STG alone (68.0 ± 3.2 vs. 46 .4 ± 4.82 vessels/HPF, P < 0.01). This increase in microvascular density was observed for both capillary (48.5 ± 5.5 vs. 38.7 ± 4.8 vessels/HPF) and arteriolar (13.3 ± 1.8 vs. 7.8 ± 1.1 vessels/HPF) density. There was no significant change in vessel density between the PBS and PBS þ EV groups (46.7 ± 4.5 vs. 42 .3 ± 2.0 vessels/HPF). This may be a result of limited EV retention in the myocardium without STG encapsulation.
STG treatment alone increases recruitment of inflammatory cells
Quantification of CD11b expression in the ischaemic border zone after treatment with PBS Control, STG Control, and STG þ EV showed increased inflammation in the STG Control and STG þ EV groups compared with PBS Control 2 days after MI and treatment injection (P < 0.05). However, the addition of EVs to the treatment did not increase inflammatory cell recruitment from the baseline amount seen with injection of the empty STG. The increased border zone inflammation resolved by 4 weeks, and CD11b expression was no different in PBS Control compared with STG Control and STG þ EV (Figure 7 ).
STG 1 EVs improves border zone remodeling postinfarction
Four weeks after LAD ligation and MI, all hearts demonstrated distinct areas of transmural infarct in addition to variable amounts of healthy 
Discussion
The purpose of this study was to advance the clinical translatability of angiogenic progenitor cell therapy through intramyocardial delivery of EVs within a gel, eliminating the obstacles associated with cell therapy. Using ESPVR as the primary measure of treatment effect, we demonstrated that paracrine factors alone can provide the same improvements in haemodynamic outcomes as progenitor cell therapy in the treatment of ischaemic myocardial insult. This is the first known report of an injectable hydrogel system for sustained EV delivery in the myocardium. Starting with an isolation technique that reproducibly yielded an exosome-enriched fraction of EVs, we elucidated potential mechanisms of the observed positive haemodynamics effects via proteomic evidence of crucial therapeutic pathways and demonstration that EPC-derived EVs were taken up by resident endothelial cells to produce a robust angiogenic response. ESPVR increased 82% with STG þ EV compared with PBS controls, whereas EV alone and STG alone produced a 56 and 43% increase in ESPVR compared with 
PBS, respectively. It is thus clear that although each component had therapeutic potential when delivered as a standalone therapy, by delivering potent EVs by direct injection within a gel with controlled-release pharmacodynamic properties, the effect of the EVs was greatly potentiated. Secondary outcomes of peri-infarct vascular proliferation and myocardial scar thickness after MI were also enhanced with STG þ EV treatment and were corroborated by proteomic analysis of EV content.
To parse out the various sources of treatment effect in this study, we saw a significant, though modest, improvement in ESPVR 4 weeks after LAD ligation and treatment injection comparing PBS Control and PBS þ EV. This demonstrated a treatment effect of the isolated EVs alone.
The empty gel (STG Control) also conferred a significant advantage in ESPVR 4 weeks after MI compared with PBS Control. HA is a biologically active proangiogenic molecule, exerting effects on endothelial cell by pressure-volume catheter of rat hearts 4 weeks after MI and untreated (PBS Control) or treated with combinations of the STG, EVs, or EPCs (*P < 0.05, **P < 0.01). Sample sizes were as follows: PBS Control, n = 10; STG Control, n = 10; PBS þ EV, n = 9; STG þ EV, n = 11; STG þ EPC, n = 10. Abbreviations: ESPVR, end systolic pressure-volume relationship; þdP/dt, maximum change in systolic pressure over time; -dP/dt, maximum change in diastolic pressure over time; EDPVR, end-diastolic pressure-volume relationship. 
proliferation, migration, and tubule formation through CD44 and receptor for HA-mediated cell motility signalling. 42 Furthermore, the stiffness of the STG may serve to mechanically stabilize the infarct border zone and reduce stress in this region. 43 In line with previous studies of HAbased hydrogels, 44 we detected an early increase in inflammation in the ischaemic border zone after injection of the STG that was not modified by the addition of EVs to the STG. This inflammation may aid in early infarct remodelling and had resolved by 4 weeks after MI.
Our data suggest that a dynamic interaction existed between EVs and STG with the STG þ EV therapy having significant advantages over STG Control in ESPVR. Similarly, the STG þ EV treatment was significantly more effective than PBS þ EV, likely owing to the sustained release of EVs from the STG and the resulting prolonged exposure of the border zone myocardium to EVs in the STG þ EV group compared with the PBS þ EV group. Extrapolating from experiences with cell-based therapy, it is likely that the small size of EVs resulted in rapid washout from the myocardium soon after injection when delivered in PBS.
Finally, we found that STG þ EV and STG þ EPC were equivalent in the treatment of ischaemic myocardium when judged by our defined Sample sizes were as follows: PBS Control, n = 8; STG Control, n = 9; PBS þ EV, n = 9; STG þ EV, n = 10; STG þ EPC, n = 7 (*P < 0.05, **P < 0.01).
endpoints. Although STG allowed the sustained release of the EVs over an extended period of time, EPCs were likely also producing EVs that were slowly released into the myocardium. These in vivo measures, along with the proteomic overlap between EVs and EPCs, convincingly demonstrated that EVs alone were sufficient to produce similar therapeutic benefits to the EPCs from which they were derived. However, EVsespecially the sizable exosome component-provided important advantages over cell-based therapy.
Our study corroborates the results of numerous previous studies that have shown a correlation between increased peri-infarct angiogenesis and improved haemodynamic function. 45 Improving the supply of oxygen-and nutrient-rich blood to the peri-infarct cardiomyocytes led to preserved contractility, while cardiomyocytes in the infarct border zone underwent hibernation with resultant contractile dysfunction in the setting of chronic ischaemia. 46 Functional outcomes were further supported by histologic analyses revealing significantly thicker scars in our therapeutic treatment groups. Our measurement of scar thickness reflected the thickness of the border zone, as thickness was calculated by averaging the scar midpoint and the peripheral scar/border zone region located on either end. Increased angiogenesis in the border zone of treated hearts likely improved local cardiomyocyte recovery and decreased adverse ventricular remodelling in the peri-infarct region, thereby minimizing thinning of infarcts and preserving global ventricular geometry. As a result, the end diastolic volume was significantly lower in STG þ EV and STG þ EPC animals compared with PBS Control. Given the progressive dilation of the heart after infarct with asymmetric expansion of the remote myocardium compared with the collagen scar, we found scar length to be unreliable as its measurement was confounded by the presumed treatment effect. There are several limitations to this study. Although ultracentrifugation and polymer-based precipitation methods are efficient and widely used methods of EV isolation, these methods did not completely eliminate non-EV material from the CM isolate. Furthermore, the quantification of in vitro angiogenesis under normoxic conditions in our study did not fully mirror the in vivo model in which the EVs were injected into an acutely ischaemic myocardium. However, given the complex compensatory mechanisms which were stimulated in vivo in the face of an ischaemic insult, simply performing in vitro angiogenesis assays in hypoxic environments was unlikely to fully capture the true effect of ischaemia within an animal model. To improve the mechanistic understanding of EV induced angiogenesis, a 3D angiogenesis assay such as the in vivo Matrigel plug assay in ischaemic tissue may be of interest.
This study has established significant foundational knowledge regarding the therapeutic value of EPC-derived EVs, but to understand the full potential of this treatment, many future projects remain. An exciting avenue for future development of EV therapy revolves around a better understanding of how environmental conditions can be manipulated to alter the essential cargo packaged within EVs. Furthermore, the benefits of using STG as a vehicle for EV delivery could be translated to the clinical setting via percutaneous catheter injections after acute MI, and large animal studies are needed to scale and trial this approach. Further detailed investigation into the immunogenicity of EVs will inform the therapeutic strategy for EV use in large animals, and eventual clinical human applications.
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